1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. U.S. Liquid Biopsy Market, by Biomarker Type
7.1.1. Circulating Tumor Cells (CTCs)
7.1.1.1. Market Revenue and Forecast
7.1.2. Circulating Tumor DNA (ctDNA)
7.1.2.1. Market Revenue and Forecast
7.1.3. Extracellular Vesicles (Exosomes & Microvesicles)
7.1.3.1. Market Revenue and Forecast
7.1.4. RNA (microRNA, mRNA)
7.1.4.1. Market Revenue and Forecast
7.1.5. Proteins
7.1.5.1. Market Revenue and Forecast
7.1.6. Others (e.g., metabolites)
7.1.6.1. Market Revenue and Forecast
8.1. U.S. Liquid Biopsy Market, by Technology/Platform
8.1.1. Next-Generation Sequencing (NGS)
8.1.1.1. Market Revenue and Forecast
8.1.2. PCR-based Methods
8.1.2.1. Market Revenue and Forecast
8.1.3. Microarrays
8.1.3.1. Market Revenue and Forecast
8.1.4. Beads, Emulsions, Amplification, and Magnetics (BEAMing)
8.1.4.1. Market Revenue and Forecast
8.1.5. Epigenetic Analysis
8.1.5.1. Market Revenue and Forecast
8.1.6. Immunoassays (for protein biomarkers)
8.1.6.1. Market Revenue and Forecast
9.1. U.S. Liquid Biopsy Market, by Test Type / Application Stage
9.1.1. Screening / Early Detection
9.1.1.1. Market Revenue and Forecast
9.1.2. Diagnosis
9.1.2.1. Market Revenue and Forecast
9.1.3. Prognosis
9.1.3.1. Market Revenue and Forecast
9.1.4. Therapy Selection / Companion Diagnostics
9.1.4.1. Market Revenue and Forecast
9.1.5. Minimal Residual Disease (MRD) Detection
9.1.5.1. Market Revenue and Forecast
9.1.5. Recurrence Monitoring / Surveillance
9.1.5.1. Market Revenue and Forecast
9.1.5. Treatment Response Monitoring
9.1.5.1. Market Revenue and Forecast
10.1. U.S. Liquid Biopsy Market, by Cancer Type (Indication Area)
10.1.1. Lung Cancer (NSCLC, SCLC)
10.1.1.1. Market Revenue and Forecast
10.1.2. Breast Cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Colorectal Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Prostate Cancer
10.1.4.1. Market Revenue and Forecast
10.1.5. Pancreatic Cancer
10.1.5.1. Market Revenue and Forecast
10.1.6. Ovarian Cancer
10.1.6.1. Market Revenue and Forecast
10.1.7. Pancreatic Cancer
10.1.7.1. Market Revenue and Forecast
10.1.8. Melanoma
10.1.8.1. Market Revenue and Forecast
10.1.9. Bladder Cancer
10.1.9.1. Market Revenue and Forecast
10.1.10. Liver Cancer
10.1.10.1. Market Revenue and Forecast
10.1.11. Others (e.g., hematological malignancies)
10.1.11.1. Market Revenue and Forecast
11.1. U.S. Liquid Biopsy Market, by Product & Service Type
11.1.1. Kits & Reagents
11.1.1.1. Market Revenue and Forecast
11.1.2. Instruments/Devices
11.1.2.1. Market Revenue and Forecast
11.1.3. Software & Bioinformatics Tools
11.1.3.1. Market Revenue and Forecast
11.1.4. Services
11.1.4.1. Market Revenue and Forecast
12.1. U.S. Liquid Biopsy Market, by Clinical Setting / End-User
12.1.1. Hospitals & Clinics
12.1.1.1. Market Revenue and Forecast
12.1.2. Reference Laboratories
12.1.2.1. Market Revenue and Forecast
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast
12.1.4. Contract Research Organizations (CROs)
12.1.4.1. Market Revenue and Forecast
12.1.5. Government & Public Health Agencies
12.1.5.1. Market Revenue and Forecast
13.1. U.S. Liquid Biopsy Market, by Sample Type
13.1.1. Blood (Plasma/Serum)
13.1.1.1. Market Revenue and Forecast
13.1.2. Urine
13.1.2.1. Market Revenue and Forecast
13.1.3. Saliva
13.1.3.1. Market Revenue and Forecast
13.1.4. Cerebrospinal Fluid (CSF)
13.1.4.1. Market Revenue and Forecast
13.1.5. Other Biofluids (e.g., pleural effusion, ascites)
13.1.5.1. Market Revenue and Forecast
14.1. U.S. Liquid Biopsy Market, by Business Model
14.1.1. Test Kit Manufacturers
14.1.1.1. Market Revenue and Forecast
14.1.2. Test Kit Manufacturers
14.1.2.1. Market Revenue and Forecast
14.1.3. Test Kit Manufacturers
14.1.3.1. Market Revenue and Forecast
14.1.4. Direct-to-Consumer (DTC) Testing Models
14.1.4.1. Market Revenue and Forecast
14.1.5. Direct-to-Consumer (DTC) Testing Models
14.1.5.1. Market Revenue and Forecast
15.1. North America
15.1.1. Market Revenue and Forecast, by Biomarker Type
15.1.2. Market Revenue and Forecast, by Technology/Platform
15.1.3. Market Revenue and Forecast, by Test Type / Application Stage
15.1.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.1.5. Market Revenue and Forecast, by Product & Service Type
15.1.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.1.7. Market Revenue and Forecast, by Sample Type
15.1.8. Market Revenue and Forecast, by Business Model
15.1.9. U.S.
15.1.9.1. Market Revenue and Forecast, by Biomarker Type
15.1.9.2. Market Revenue and Forecast, by Technology/Platform
15.1.9.3. Market Revenue and Forecast, by Test Type / Application Stage
15.1.9.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.1.9.5. Market Revenue and Forecast, by Product & Service Type
15.1.9.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.1.9.7. Market Revenue and Forecast, by Sample Type
15.1.9.8. Market Revenue and Forecast, by Business Model
15.1.10. Rest of North America
15.1.10.1. Market Revenue and Forecast, by Biomarker Type
15.1.10.2. Market Revenue and Forecast, by Technology/Platform
15.1.10.3. Market Revenue and Forecast, by Test Type / Application Stage
15.1.10.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.1.10.5. Market Revenue and Forecast, by Product & Service Type
15.1.10.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.1.10.7. Market Revenue and Forecast, by Sample Type
15.1.10.8. Market Revenue and Forecast, by Business Model
15.2. Europe
15.2.1. Market Revenue and Forecast, by Biomarker Type
15.2.2. Market Revenue and Forecast, by Technology/Platform
15.2.3. Market Revenue and Forecast, by Test Type / Application Stage
15.2.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.2.5. Market Revenue and Forecast, by Product & Service Type
15.2.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.2.7. Market Revenue and Forecast, by Sample Type
15.2.8. Market Revenue and Forecast, by Business Model
15.2.9. UK
15.2.9.1. Market Revenue and Forecast, by Biomarker Type
15.2.9.2. Market Revenue and Forecast, by Technology/Platform
15.2.9.3. Market Revenue and Forecast, by Test Type / Application Stage
15.2.9.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.2.9.5. Market Revenue and Forecast, by Product & Service Type
15.2.9.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.2.9.7. Market Revenue and Forecast, by Sample Type
15.2.9.8. Market Revenue and Forecast, by Business Model
15.2.10. Germany
15.2.10.1. Market Revenue and Forecast, by Biomarker Type
15.2.10.2. Market Revenue and Forecast, by Technology/Platform
15.2.10.3. Market Revenue and Forecast, by Test Type / Application Stage
15.2.10.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.2.10.5. Market Revenue and Forecast, by Product & Service Type
15.2.10.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.2.10.7. Market Revenue and Forecast, by Sample Type
15.2.10.8. Market Revenue and Forecast, by Business Model
15.2.11. France
15.2.11.1. Market Revenue and Forecast, by Biomarker Type
15.2.11.2. Market Revenue and Forecast, by Technology/Platform
15.2.11.3. Market Revenue and Forecast, by Test Type / Application Stage
15.2.11.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.2.11.5. Market Revenue and Forecast, by Product & Service Type
15.2.11.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.2.11.7. Market Revenue and Forecast, by Business Model
15.2.11.8. Market Revenue and Forecast, by Sample Type
15.2.12. Rest of Europe
15.2.12.1. Market Revenue and Forecast, by Biomarker Type
15.2.12.2. Market Revenue and Forecast, by Technology/Platform
15.2.12.3. Market Revenue and Forecast, by Test Type / Application Stage
15.2.12.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.2.12.5. Market Revenue and Forecast, by Product & Service Type
15.2.12.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.2.12.7. Market Revenue and Forecast, by Sample Type
15.2.12.8. Market Revenue and Forecast, by Business Model
15.3. APAC
15.3.1. Market Revenue and Forecast, by Biomarker Type
15.3.2. Market Revenue and Forecast, by Technology/Platform
15.3.3. Market Revenue and Forecast, by Test Type / Application Stage
15.3.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.3.5. Market Revenue and Forecast, by Product & Service Type
15.3.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.3.7. Market Revenue and Forecast, by Sample Type
15.3.8. Market Revenue and Forecast, by Business Model
15.3.9. India
15.3.9.1. Market Revenue and Forecast, by Biomarker Type
15.3.9.2. Market Revenue and Forecast, by Technology/Platform
15.3.9.3. Market Revenue and Forecast, by Test Type / Application Stage
15.3.9.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.3.9.5. Market Revenue and Forecast, by Product & Service Type
15.3.9.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.3.9.7. Market Revenue and Forecast, by Sample Type
15.3.9.8. Market Revenue and Forecast, by Business Model
15.3.10. China
15.3.10.1. Market Revenue and Forecast, by Biomarker Type
15.3.10.2. Market Revenue and Forecast, by Technology/Platform
15.3.10.3. Market Revenue and Forecast, by Test Type / Application Stage
15.3.10.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.3.10.5. Market Revenue and Forecast, by Product & Service Type
15.3.10.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.3.10.7. Market Revenue and Forecast, by Sample Type
15.3.10.8. Market Revenue and Forecast, by Business Model
15.3.11. Japan
15.3.11.1. Market Revenue and Forecast, by Biomarker Type
15.3.11.2. Market Revenue and Forecast, by Technology/Platform
15.3.11.3. Market Revenue and Forecast, by Test Type / Application Stage
15.3.11.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.3.11.5. Market Revenue and Forecast, by Product & Service Type
15.3.11.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.3.11.7. Market Revenue and Forecast, by Sample Type
15.3.11.8. Market Revenue and Forecast, by Business Model
15.3.12. Rest of APAC
15.3.12.1. Market Revenue and Forecast, by Biomarker Type
15.3.12.2. Market Revenue and Forecast, by Technology/Platform
15.3.12.3. Market Revenue and Forecast, by Test Type / Application Stage
15.3.12.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.3.12.5. Market Revenue and Forecast, by Product & Service Type
15.3.12.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.3.12.7. Market Revenue and Forecast, by Sample Type
15.3.12.8. Market Revenue and Forecast, by Business Model
15.4. MEA
15.4.1. Market Revenue and Forecast, by Biomarker Type
15.4.2. Market Revenue and Forecast, by Technology/Platform
15.4.3. Market Revenue and Forecast, by Test Type / Application Stage
15.4.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.4.5. Market Revenue and Forecast, by Product & Service Type
15.4.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.4.7. Market Revenue and Forecast, by Sample Type
15.4.8. Market Revenue and Forecast, by Business Model
15.4.9. GCC
15.4.9.1. Market Revenue and Forecast, by Biomarker Type
15.4.9.2. Market Revenue and Forecast, by Technology/Platform
15.4.9.3. Market Revenue and Forecast, by Test Type / Application Stage
15.4.9.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.4.9.5. Market Revenue and Forecast, by Product & Service Type
15.4.9.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.4.9.7. Market Revenue and Forecast, by Sample Type
15.4.9.8. Market Revenue and Forecast, by Business Model
15.4.10. North Africa
15.4.10.1. Market Revenue and Forecast, by Biomarker Type
15.4.10.2. Market Revenue and Forecast, by Technology/Platform
15.4.10.3. Market Revenue and Forecast, by Test Type / Application Stage
15.4.10.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.4.10.5. Market Revenue and Forecast, by Product & Service Type
15.4.10.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.4.10.7. Market Revenue and Forecast, by Sample Type
15.4.10.8. Market Revenue and Forecast, by Business Model
15.4.11. South Africa
15.4.11.1. Market Revenue and Forecast, by Biomarker Type
15.4.11.2. Market Revenue and Forecast, by Technology/Platform
15.4.11.3. Market Revenue and Forecast, by Test Type / Application Stage
15.4.11.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.4.11.5. Market Revenue and Forecast, by Product & Service Type
15.4.11.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.4.11.7. Market Revenue and Forecast, by Sample Type
15.4.11.8. Market Revenue and Forecast, by Business Model
15.4.12. Rest of MEA
15.4.12.1. Market Revenue and Forecast, by Biomarker Type
15.4.12.2. Market Revenue and Forecast, by Technology/Platform
15.4.12.3. Market Revenue and Forecast, by Test Type / Application Stage
15.4.12.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.4.12.5. Market Revenue and Forecast, by Product & Service Type
15.4.12.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.4.12.7. Market Revenue and Forecast, by Sample Type
15.4.12.8. Market Revenue and Forecast, by Business Model
15.5. Latin America
15.5.1. Market Revenue and Forecast, by Biomarker Type
15.5.2. Market Revenue and Forecast, by Technology/Platform
15.5.3. Market Revenue and Forecast, by Test Type / Application Stage
15.5.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.5.5. Market Revenue and Forecast, by Product & Service Type
15.5.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.5.7. Market Revenue and Forecast, by Sample Type
15.5.8. Market Revenue and Forecast, by Business Model
15.5.9. Brazil
15.5.9.1. Market Revenue and Forecast, by Biomarker Type
15.5.9.2. Market Revenue and Forecast, by Technology/Platform
15.5.9.3. Market Revenue and Forecast, by Test Type / Application Stage
15.5.9.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.5.9.5. Market Revenue and Forecast, by Product & Service Type
15.5.9.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.5.9.7. Market Revenue and Forecast, by Sample Type
15.5.9.8. Market Revenue and Forecast, by Business Model
15.5.10. Rest of LATAM
15.5.10.1. Market Revenue and Forecast, by Biomarker Type
15.5.10.2. Market Revenue and Forecast, by Technology/Platform
15.5.10.3. Market Revenue and Forecast, by Test Type / Application Stage
15.5.10.4. Market Revenue and Forecast, by Cancer Type (Indication Area)
15.5.10.5. Market Revenue and Forecast, by Product & Service Type
15.5.10.6. Market Revenue and Forecast, by Clinical Setting / End-User
15.5.10.7. Market Revenue and Forecast, by Sample Type
15.5.10.8. Market Revenue and Forecast, by Business Model
16.1. ANGLE plc, Biocept Inc.
16.1.1. Company Overview
16.1.2. Product Offerings
16.1.3. Financial Performance
16.1.4. Recent Initiatives
16.2. Bio-Rad Laboratories Inc.
16.2.1. Company Overview
16.2.2. Product Offerings
16.2.3. Financial Performance
16.2.4. Recent Initiatives
16.3. Epigenomics AG
16.3.1. Company Overview
16.3.2. Product Offerings
16.3.3. Financial Performance
16.3.4. Recent Initiatives
16.4. Exact Sciences Corporation
16.4.1. Company Overview
16.4.2. Product Offerings
16.4.3. Financial Performance
16.4.4. Recent Initiatives
16.5. F. Hoffmann-La Roche AG
16.5.1. Company Overview
16.5.2. Product Offerings
16.5.3. Financial Performance
16.5.4. Recent Initiatives
16.6. Guardant Health Inc.
16.6.1. Company Overview
16.6.2. Product Offerings
16.6.3. Financial Performance
16.6.4. Recent Initiatives
16.7. Guardant Health Inc.
16.7.1. Company Overview
16.7.2. Product Offerings
16.7.3. Financial Performance
16.7.4. Recent Initiatives
16.8. MDxHealth SA
16.8.1. Company Overview
16.8.2. Product Offerings
16.8.3. Financial Performance
16.8.4. Recent Initiatives
16.9. Menarini Silicon Biosystems
16.9.1. Company Overview
16.9.2. Product Offerings
16.9.3. Financial Performance
16.9.4. Recent Initiatives
16.10. Menarini Silicon Biosystems
16.10.1. Company Overview
16.10.2. Product Offerings
16.10.3. Financial Performance
16.10.4. Recent Initiatives
16.7. Primary Research
16.7. Secondary Research
16.7. Assumptions
18.1. About Us
18.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
